

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Apixaban (2016) - Bristol Myers Squibb : Apixaban (2016) - Bayer : Aspirin, rivaroxaban (2016) - Abbott : BVS (2016) - MEDSCAPE-the heart.org : Inespecific (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016) - Astra Zeneca : Ticagrelor (2016) - Ferrer Internacional : Trinomia (polypill) (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2016) - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
Byrne Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : Vascular intervention (2016) - Biotronik : Vascular intervention (2016) - B.Braun : Vascular intervention (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - HeartFlow : Imaging analysis (2016) - Boston Scientific : Vascular intervention (2016)
Collet Jean-Philippe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS : apixaban (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016) - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016) - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016)
Costa Francesco	Nothing to be declared (2016)
Jeppsson Anders	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drugs (2016) - CSL Behring : Hemostasis (2016) - Octapharma : Hemostasis (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Regenerative medicine (2016)
Juni Peter	Nothing to be declared (2016)
Kastrati Adnan	Nothing to be declared (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Kolh Philippe H	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2016) - B.Braun : Surgical instruments (2016)
Levine Glenn N	Nothing to be declared (2016)
Mauri Laura	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : antiplatelet medication (2016) - CorVia : Atrial septostomy for heart failure (2016) - Biotronik : Drug Eluting Stent (2016) - Amgen : PCSK - 9 Inhibitor (2016) - Recor Medical : renal denervation (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2016) D - Research funding (departmental or institutional). - Boehringer-Ingelheim : anticoagulation (2016) - Abbott Vascular : drug-eluting scaffold (2016) - Boston Scientific : drug-eluting stent (2016) - Biotronik : drug-eluting stent (2016) - CorVia : heart failure (2016) - Amgen : PCSK-9 Inhibitor (2016)
Montalescot Gilles	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : cardiovascular disease (2016) - Bayer : cardiovascular disease (2016) - Medtronic : cardiovascular disease (2016) - Pfizer : cardiovascular disease (2016) - Servier : cardiovascular disease (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Actelion : cardiovascular disease (2016) - Sanofi Aventis : cardiovascular disease (2016) - Menarini : cardiovascular disease (2016) - WebMD : cardiovascular disease (2016) - Europa : cardiovascular disease (2016) - Lead-Up : cardiovascular disease (2016) - INSERM : cardiovascular disease (2016) - Elsevier : cardiovascular disease (2016) - MSD : cardiovascular disease (2016) - Astrazeneca : cardiovascular disease (2016) - Daiichi-Sankyo : cardiovascular disease (2016) - Boehringer Ingelheim : cardiovascular disease (2016) - Eli-lilly : cardiovascular disease (2016) - Bristol-Myers Squibb : cardiovascular disease (2016) - Beth Israel Deaconess Medical : cardiovascular disease (2016) - CME Resources : cardiovascular disease (2016) - TIMI Study Group : cardiovascular disease (2016) - Brigham Women's Hospital : cardiovascular disease (2016) - CCC : cardiovascular disease (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : cardiovascular disease (2016) - Bayer : cardiovascular disease (2016) - Boehringer-Ingelheim : cardiovascular disease (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Daiichi Sankyo : cardiovascular disease (2016) - Eli Lilly : cardiovascular disease (2016) - Medtronic : cardiovascular disease (2016) - Pfizer : cardiovascular disease (2016) - Sanofi Aventis : cardiovascular disease (2016) - Bristol Myers Squibb : cardiovascular disease (2016) - MSD : cardiovascular disease (2016) - Celladon : cardiovascular disease (2016) - Astrazeneca : cardiovascular disease (2016) - ICAN : cardiovascular disease (2016) - Fédération Francaise de Cardiologie : cardiovascular disease (2016)
Neumann Franz Josef	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant Therapy (2016) - Daiichi Sankyo : Anticoagulant therapy (2016) - Pfizer : Anticoagulant therapy (2016) - Bayer Healthcare : Anticoagulant therapy (2016) - Bristol Myers Squibb : Anticoagulant therapy (2016) - Astra Zeneca : Antiplatelet therapy (2016) - Boston Scientific : Interventional cardiology (2016) - Edwards Lifesciences : Transcatheter valves (2016) - Medtronic : Transcatheter valves (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulant therapy (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Neumann Franz Josef	<ul style="list-style-type: none"> - Novartis : Heart failure (2016) - Pfizer : Heart failure (2016) - GlaxoSmithKline : Heart failure (2016) - Biotronik : Interventional Cardiology (2016) - Abbott Vascular : MitraClip (2016) - Edwards Lifesciences : Transcatheter Valves (2016) - Medtronic : Transcatheter Valves (2016)
Petricevic Mate	Nothing to be declared (2016)
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Terumo Inc : coronary catheters (2016) - Johnson & Johnson : coronary catheters (2016) - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Biotronik : devices (2016) - Terumo Inc : devices (2016) - Abbott Vascular : devices (2016)
Steg Philippe Gabriel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : antianginal agents (2016) - Bayer : anticoagulants (2016) - Astra Zeneca : antiplatelet agents (2016) - Daiichi Sankyo : antiplatelet agents (2016) - Boehringer-Ingelheim : antithrombotics (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Steg Philippe Gabriel	<ul style="list-style-type: none"> - Janssen-Cilag : antithrombotics (2016) - Sanofi Aventis : antithrombotics (2016) - GlaxoSmithKline : antithrombotics (2016) - Medicines Company : antithrombotics (2016) - Bristol Myers Squibb : antithrombotics (2016) - Lilly : antithrombotics and lipid lowering drugs (2016) - Novartis : consulting (2016) - Pfizer : Events adjudication committee (2016) - Amarin : Lipid compounds (2016) - CSL Behring : lipid lowering drugs (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Sanofi Aventis : Clinical trial on lipids (2016) - Servier : Registry on coronary artery disease (2016)
Valgimigli Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet agents (2016) - Terumo Inc : Coronary stent (2016) - Abbott Vascular : Coronary Stent (2016) - Sinomed : Coronary stent (2016) - Bayer : Oral anticoagulation (2016) - Correvio : Tirofiban (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti platelet agents (2016) - Medicure : Antiplatelet agents (2016) - Terumo Inc : Coronary stent (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Task Force Members



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Valgimigli Marco	- The Medicines Company : parenteral anticoagulation (2016)
Windecker Stephan	D - Research funding (departmental or institutional). - Boston Scientific : General Cardiology (2016) - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016) - Bracco Pharmaceutical : General Cardiology (2016)
Zamorano Gomez Jose Luis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016) - Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) D - Research funding (departmental or institutional). - Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott : Epidemiology study of Mitral regurgitation (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Hyperlipidemia (2016) - Novartis : Hypertension (2016) - Boehringer-Ingelheim : Oral anticoagulation (2016) - Bayer Healthcare : Oral anticoagulation (2016) - Pfizer/BMS alliance : Oral anticoagulation (2016)
Addad Faouzi	Nothing to be declared (2016)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet treatment (2016)
Alexopoulos Dimitrios	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulants (2016) - Boehringer-Ingelheim : anticoagulants (2016) - Astra Zeneca : antiplatelets (2016) - Medicines Company : antiplatelets (2016)
Aliyev Farid	Nothing to be declared (2016)
Andreotti Felicita	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : apixaban (2016) - BMS : apixaban (2016) - Boehringer Ingelheim : dabigatran (2016) - Amgen : dyslipidemia (2016) - Daiichi Sankyo : edoxaban (2016) - International Menarini Foundation : prevention of cardiovascular disease (2016) - Bayer Schering Pharma : rivaroxaban (2016) - Medscape : stroke prevention in atrial fibrillation (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Antman Elliott	D - Research funding (departmental or institutional). - TIMI group : multiple research grants to this ARO ---managed through our Department of Medicine at our Hospital (2016)
Antonijevic Nebojsa	Nothing to be declared (2016)
Aydogdu Sinan	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Antihyperlipidemics (2016) - Astra Zeneca : Antiplatelets (2016) - Daiichi Sankyo : Antiplatelets (2016) - Bayer : Oral anticoagulant agents (2016) - Boehringer-Ingelheim : oral anticoagulants (2016) - Pfizer : oral anticoagulants (2016)
Badimon Lina	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Lipids (2016) - Burson Masteller : Nutrition (2016) - Astra Zeneca : Thrombosis (2016) D - Research funding (departmental or institutional). - Astrazeneca : Thrombosis (2016)
Barbato Emanuele	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Education courses on rotational atherectomy (2016) - St Jude Medical : Educational courses on FFR (2016) D - Research funding (departmental or institutional). - St Jude Medical : Unrestricted grant for an investigator-driven study (2016)
Bassand Jean-Pierre	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Aspen : anticoagulant (2016)
Budaj Andrzej	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : alirocumab (2016) - Bristol Myers Squibb/Pfizer : apixaban (2016) - Novartis : canakinumab (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Budaj Andrzej	<ul style="list-style-type: none"> - Boehringer-Ingelheim : dabigatran (2016) - GlaxoSmithKline : darapladib, losmapimod (2016) - Eisai : lorcaserin (2016) - Astra Zeneca : ticagrelor, dapagliflozin (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2016) - Bristol Myers Squibb/Pfizer : apixaban (2016) - Novartis : canakinumab (2016) - Boehringer-Ingelheim : dabigatran (2016) - GlaxoSmithKline : darapladib, losmapimod (2016) - Eisai : lorcaserin (2016) - Astra Zeneca : ticagrelor, dapagliflozin (2016)
Bugiardini Raffaele	Nothing to be declared (2016)
Cherradi Rhizlan	Nothing to be declared (2016)
Cikirikcioglu Mustafa	Nothing to be declared (2016)
Coman Ioan Mircea	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016) - Johnson & Johnson : antithrombotic (2016) - Bayer AG : antithrombotic (2016) - Sanofi Aventis : dyslipidemia (2016) - Fournier Laboratories : dyslipidemia (2016) - Amgen Inc : dyslipidemia , (2016) - Novartis : HF (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Vifor International : iron deficiency (2016) - Actelion : PHT (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016) - Johnson & Johnson : antithrombotic (2016) - Bayer AG : antithrombotic (2016) - Sanofi Aventis : dyslipidemia (2016) - Amgen Inc : dyslipidemia (2016) - Fournier Laboratories : dyslipidemia (2016) - Novartis : HF (2016) - Vifor International : iron deficiency (2016) - Actelion : PHT (2016)
Cuisset Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : DES (2016) - Biotronik : DES (2016) - Abbott Vascular : DES (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Clopidogrel (2016) - Eli Lilly : Prasugrel (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biomatrix : DES (2016) - Europa : Education (2016) - Bayer : Rivaroxaban (2016) - Hexacath : Stent (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Cuisset Thomas	<ul style="list-style-type: none"> - Edwards Lifesciences : TAVI (2016) - Astra Zeneca : Ticagrelor (2016)
De Bonis Michele	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : valve prostheses (2016)
De Luca Leonardo	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : dabigatran (2016) - Daiichi Sankyo : prasugrel (2016) - Menarini : Ranolazine (2016) - Bayer : rivaroxaban (2016) - Astra Zeneca : ticagrelor (2016)
Delgado Victoria	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Mitraclip (2016) D - Research funding (departmental or institutional). - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016)
Desmet Walter	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Interventional Cardiology (2016) - Abbott Vascular : Interventional Cardiology (2016)
Duplyakov Dmitry	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Dabigatran (2016) - Berlin Chemie AG : Ranolazine (2016) - Bayer Healthcare : Rivaroxaban (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Duplyakov Dmitry	- Astra Zeneca : Ticagrelor (2016)
Eritsland Jan	Nothing to be declared (2016)
Fitzsimons Donna	Nothing to be declared (2016)
Fras Zlatko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2016) - Boehringer-Ingelheim : empagliflozin (diabetes & CVD) (2016) - Amgen : evolocumab (2016) - Astra Zeneca : ticagrelor (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Duke Clinical Research Institute : alirocumab (2016) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Duke Clinical Research Institute : alirocumab (2016)
Gaemperli Oliver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016)
Galie Nazzareno	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - GSK : Ambrisentan and Tadalafil (2016) - Actelion : macitentan, selexipag (2016) - Bayer Healthcare : Riociguat (2016) - Pfizer : sildenafil (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - GSK : ambrisentan and Tadalafil (2016) - Bayer Healthcare : riociguat (2016) - Actelion : Selexipag (2016) - Pfizer : sildenafil (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Georgiou Georgios P	Nothing to be declared (2016)
Gilard Martine	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : medication (2016) - Medtronic : TAVI (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : medication (2016) - Terumo Inc : OCT/stent (2016) - Abbott Vascular : Stent (2016) - Edwards Lifesciences : TAVI (2016) - GE Healthcare : Technology (2016)
Grove Erik Lerkevang	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol-Myers Squibb : apixaban (2016) - Boehringer-Ingelheim : dabigatran (2016) - Pfizer : dalteparin + apixaban (2016) - Merck Sharp & Dohme : Edoxaban (2016) - Bayer : rivaroxaban (2016) - Astrazeneca : ticagrelor / ACS (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor, investigator in 'THEMIS' study (2016)
Gudmundsdottir Ingibjorg Jona	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : PCSK9-inhibitor: participation in GLAGOV study (2016)
Haliti Edmond	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Krka Pharma : ARB (2016) - Novartis : ARB+Amlodipin (2016)
Hamm Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : drugs (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Hamm Christian	<ul style="list-style-type: none"> - Boehringer-Ingelheim : drugs (2016) - Daiichi Sankyo : drugs (2016) - Novartis : drugs (2016) - Pfizer : drugs (2016) - Sanofi Aventis : drugs (2016) - GlaxoSmithKline : drugs (2016) - Lilly : drugs (2016) - Heart.org : drugs (2016) - Bayer Healthcare : drugs (2016) - Medicines Company : drugs (2016) - Merck Sharp & Dohme : drugs (2016) - Abbott Vascular : interventional devices (2016) - BRAHMS GmbH : markers (2016) - Siemens Healthcare : MRI (2016) - Boston Scientific : PCI (2016) - Medtronic : PCI, Valves (2016) - TIMI group : study advisor (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Deutsche Forschungsgemeinschaft : experimental (2016) - German Research Foundation : experimental studies (2016)
Hindricks Gerhard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<ul style="list-style-type: none"> - Biotronik : CIEDs and interventional electrophysiology (2016) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016)
Huijnen Steve	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation therapy (2016)
Ibanez Borja	<ul style="list-style-type: none"> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Astra Zeneca : I am Co-PI of a multicenter scientific grant for a study on behavioral change for primary prevention, NO drugs or products involved. (2016)
Iung Bernard	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016)
James Stefan	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Bayer : Anti coagulation (2016) - Boston Scientific : Stents (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Medicines Company : Anti thrombotics (2016) - Astra Zeneca : Antiplatelet (2016) - Abbott : Stents (2016) - Boston Scientific : stents (2016) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Astra Zeneca : Anti thrombotics (2016)
Katus Hugo	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016) - Astra Zeneca : Ticagrelor (2016) - Bayer Vital : Xarelto-NOAK (2016) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016) - Philips : MRT (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Kedev Sasko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : Speaker fees (2016) - Medtronic : Speaker fees (2016) - Terumo Inc : Speaker fees (2016) - Meril : Speaker fees (2016)
Kinnaird Tim	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Biofreedom stent (2016) - Orbus Neich : Combo stent, Scoreflex balloon (2016) - Daiichi Sankyo : Edoxaban, prasugrel (2016) - Astra Zeneca : Ticagrelor (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : Statistical research support (2016)
Kiss Robert Gabor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis steering committee member : coordination of a PCSK9 study (2016) - TIMI group steering committee member : diabetes drug therapy (2016) - Cleveland Clinic Research Foundation : fish oil (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes oral drugs (2016) - Pfizer : NOAC (2016) - Bayer AG : NOAC (2016) - Boehringer-Ingelheim : NOAC, empaglifozin (2016) - Amgen : PCSK9 inhibitor (2016) - MSD : sitagliptin, ezetimibe, edoxaban (2016)
Kiviniemi Tuomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute coronary syndrome (2016) - Bayer : Anticoagulation (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Kiviniemi Tuomas	<ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulation (2016) - Merck Sharp & Dohme : Anticoagulation (2016) - Bristol Myers Squibb Pfizer alliance : Anticoagulation (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb Pfizer alliance : Cardiac surgery (2016)
Knuuti Juhani	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - St Jude Medical : Echo course (2016) - Servier : Ischemic Heart Disease (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : NOAC (2016) - Medtronic : Structural disease (2016)
Landmesser Ulf	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : Advisory Board fees (2016) - St. Jude : Advisory Board fees (2016) - Amgen : Speaker fees (2016) - Pfizer : Speaker fees (2016) - Sanofi Aventis : Speaker fees (2016) - Berlin Chemie AG : Speaker fees (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Landmesser Ulf	<ul style="list-style-type: none"> - Roche Pharma : Speaker fees (2016) - MSD : Speaker fees, Advisory Board fees (2016) D - Research funding (departmental or institutional). - Bayer AG : Research Grant (2016)
Latkovskis Gustavs	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants (2016) - Boehringer-Ingelheim : Anticoagulants (2016) - Berlin Chemie AG : Antihypertensive agents (2016) - Sanofi Aventis : Antihypertensive therapies, risk estimation and management, prevention (2016) - Menarini : Antihypertensive therapy (2016) - Abbott Laboratories : Cardiac markers (2016) - University of Latvia : Education (2016) - Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2016) - Siemens Healthcare : hs-troponin I (2016) - Servier : Hypertension, heart rate, lipid lowering, risk reduction (2016) - Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2016) - Mylan : Lipid lowering therapies (2016) - Astra Zeneca : lipid-lowering drugs, anti platelets (2016) - Amgen : Lipid-lowering. (2016) - Riga Stradins University : Postgraduate education (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2016) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Latkovskis Gustavs	- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2016)
Leclercq Christophe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Biotronik : devices (2016) - Bayer Healthcare : DOAC (2016)
Lettino Maddalena	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulants (2016) - Aspen : Anticoagulants (2016) - Pfizer : Anticoagulants, statins (2016) - Eli Lilly : Antithrombotic agents (2016) - Daiichi Sankyo : Antithrombotic agents, anticoagulants (2016) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2016) - Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2016) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (PCK9 inhibitors) (2016) - Astra Zeneca : Antithrombotic agents, statins (2016)
Lev Eli Israel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Dabigatran - NOACS (2016) - Pfizer : Eliquis - NOACS (2016) - Astra Zeneca : Ticagrelor - antiplatelet therapy (2016) D - Research funding (departmental or institutional). - Pfizer : Eliquis - NOACS (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Lev Eli Israel	- Astra Zeneca : Ticagrelor - antiplatelet therapy (2016)
Lip Gregory Y H	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : AF screening (2016) - BMS/Pfizer : Anticoagulation (2016) - Boehringer Ingelheim : Anticoagulation (2016) - Bayer/Janssen : Anticoagulation (2016) - Daiichi-Sankyo : Daiichi-Sankyo (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - BMS/Pfizer : AF Registries [unrestricted educational grant] (2016) - Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Magri Caroline Jane	Nothing to be declared (2016)
Marandi Toomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotics (2016)
Massberg Steffen	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Roche Diagnostics : TROPICAL ACS trial (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial) co-funded (2016)
McDonagh Theresa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2016) - Novartis : Honoraria (2016)
McFadden Eugene Patrick	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelets (2016) - Abbott Vascular : Coronary Stents/scaffolds (2016) - Cardialysis : CRO (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Terumo Inc : Coronary stents (2016) - Bayer : NOAC (2016)
Mirrahimov Erkin	Nothing to be declared (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Motovska Zuzana	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelets (2016)
Parkhomenko Alexander	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BHFZ : corvitin (2016) - Sanofi Aventis : enoxaparin (2016) - Servier : preductal (2016) - Bayer Healthcare : rivaroxaban (2016) - Astra Zeneca : ticagrelor (2016) D - Research funding (departmental or institutional). - European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2017 (2016)
Petrauskiene Birute	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Apixaban (2016) - Novartis : Canakinumab (2016) - Bayer AG : Rivaroxaban (2016) - Janssen Research and development : Rivaroxaban (2016) - Astra Zeneca : Ticagrelor (2016)
Piepoli Massimo Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Committee member, Speaker fee (2016) - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Heart Failure Prevention Initiatives (2016)
Pierard Luc	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Speaker fee (2016) - Boehringer-Ingelheim : Speaker fees, Advisory Board (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Sponsorship Annual meeting (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Pierard Luc	<ul style="list-style-type: none"> - Daiichi Sankyo : Sponsorship Echocardiography course (2016) - St Jude Medical : Sponsorship Echocardiography course (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik : Research funding (2016)
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulant, diabetes (2016) - Abbott Vascular : devices (2016) - Respicardia : devices (2016) - BioControl : devices (2016) - Novartis : heart failure (2016) - Cardioentis : heart failure (2016) - Berlin Chemie AG : heart failure (2016) - Bayer Healthcare : heart failure (2016) - Vifor Pharma ltd : heart failure (2016) - CIBIEM : heart failure (2016) - Servier : heart failure, coronary artery disease (2016) - Amgen : heart failure, lipids (2016) - Pfizer : lipids (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Respicardia : anticoagulant (2016) - BioControl : devices (2016) - DC Device : devices (2016) - Novartis : heart failure (2016) - Cardioentis : heart failure (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Bayer Healthcare : heart failure (2016) - CIBIEM : heart failure (2016) - Servier : heart failure, coronary artery disease (2016) - Amgen : heart failure, lipids (2016)
Postadzhiyan Arman	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS (2016) - Bayer : AF (2016) - Boehringer-Ingelheim : AF (2016) - Pfizer : AF, dyslipidemia (2016) - Amgen : dyslipidemia (2016) - Sanofi Aventis : dyslipidemia (2016)
Richter Dimitrios	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : CAD- hypertension (2016) - Novartis : hypertension (2016) - Abbott : lipids (2016) - Amgen : lipids (2016) - Sanofi Aventis : Lipids (2016) - Lilly : Lipids (2016) - Unilever : lipids (2016) - Merck Sharp & Dohme : lipids (2016) - Angelini : Lipids (2016) - Vianex : lipids (2016) - Galenica : Lipids (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Teva Pharmaceutical Industries : lipids, hypertension (2016) - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Bayer Healthcare : Thrombosis (2016)
Roithinger Franz Xaver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2016) - Boehringer-Ingelheim : Anticoagulation (2016) - Daiichi Sankyo : Anticoagulation (2016) - St. Jude Medical : Devices (2016) - Merck Ges m b H : Diabetes (2016) - Astra Zeneca : Platelet inhibition (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation (2016) - Biotronik : Device Therapy (2016) - Biosense Webster : Electrophysiology (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : Electrophysiology (2016) - Astra Zeneca : Platelet inhibition (2016)
Schwerzmann Markus	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary hypertension (2016) - Bayer AG : Pulmonary hypertension (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Sechtem Udo	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Berlin Chemie AG : cath lab equipment (2016) - Astra Zeneca : drugs (2016) - Boehringer-Ingelheim : Drugs (2016) - Daiichi Sankyo : drugs (2016) - Novartis : Drugs (2016) - Sanofi Aventis : Drugs (2016) - Bristol Myers Squibb : Drugs (2016) - Bayer Vital GmbH : Drugs (2016)
Shlyakhto Evgeny	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Krka Pharma : Arterial Hypertension (2016) - Novartis : Arterial Hypertension, Heart Failure (2016) - Merck Sharp & Dohme : Atherosclerosis (2016) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016) - Pfizer : General Cardiology (2016)
Simpson Iain A	Nothing to be declared (2016)
Sousa Uva Miguel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Dabigatran (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2016)
Stabile Eugenio	Nothing to be declared (2016)
Stelmashok Valeriy	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Advisory boarding team member (2016)
Storey Robert	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Apixaban (2016) - Bristol Myers Squibb : Apixaban (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Storey Robert	<ul style="list-style-type: none"> - The Medicines Company : Cangrelor (2016) - PlaqueTec : LBS Device (2016) - Bayer : Rivaroxaban (2016) - Astra Zeneca : Ticagrelor (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016)
Sugraliyev Akhmetzhan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Direct oral anticoagulant (2016)
Tavares Aguiar Carlos Manuel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2016) - Pfizer : Apixaban (2016) - Bristol Myers Squibb : Apixaban (2016) - Bial Portela : Atorvastatin/Ezetimibe (2016) - Merck Sharp & Dohme : Atorvastatin/Fenofibrate (2016) - Daiichi Sankyo : Edoxaban (2016) - Boehringer-Ingelheim : Empagliflozin (2016) - Amgen : Evolocumab (2016) - Servier : Ivabradine (2016) - Novartis : LCZ696 (2016) - JaBA Recordati : Pitavastatin, Vitamin D (2016) - Tecnimede : Pravastatin/Fenofibrate, Azilsartan/Chlorthalidone (2016) - Menarini : Ranolazine, Olmesartan/Amlodipine (2016) - Bayer : Rivaroxaban (2016) - BGP Products : Simvastatin/Fenofibrate (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Tavares Aguiar Carlos Manuel	<ul style="list-style-type: none"> - Abbott : Simvastatin-Fenofibrate (2016) - Gilead : Tenofovir (2016) - Astra Zeneca : Ticagrelor, ZS-9, Dapagliflozin (2016)
Tello Montoliu Antonio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular (2016) - Astra Zeneca : Cardiovascular (2016) - Daiichi Sankyo : Cardiovascular (2016) - Merck Sharp & Dohme : Cardiovascular (2016) - Rovi : Cardiovascular (2016) - Ferrer Internacional : thrombosis (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Cardiovascular (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2016) - Daiichi Sankyo : Cardiovascular (2016) - Roche Diagnostics : Thrombosis (2016)
Ten Berg Jurrien M	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : advisory board and speakers fee (2016) - Medicines Company : advisory board fee and speakers fee (2016) - Merck Sharp & Dohme : advisory board fees (2016) - Eli Lilly : speaker fee (2016) - Pfizer : speakers fee (2016) - BMS : speakers fee (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : research funding ticagrelor (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Aspirin, Acarbose (2016) - Servier : Ivabradine (2016) - Janssen-Cilag : Rivaroxaban (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Celyad : Cell product (2016) - Servier : Ivabradine (2016) - Kowa : Pemafibrate (2016) - Janssen-Cilag : Rivaroxaban (2016)
Tsakiris Dimitrios	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Eliquis (2016) - Daiichi Sankyo : Lixiana (2016) - Bayer AG : Xarelto (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer AG : Hemophilia treatment (2016) - Baxalta (Switzerland) AG : Hemophilia treatment (2016)
Van de Werf Frans	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : tenecteplase ,dabigatran (2016) - Astra Zeneca : ticagrelor (2016) - MSD : vorapaxar,sitagliptin (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : tenecteplase (2016)
Varenhorst Christoph	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute Coronary Syndromes (2016) - Boehringer-Ingelheim : Antithrombotics (2016) - Pfizer : Antithrombotics (2016)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Varenhorst Christoph	<ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotics (2016) - Bayer AG : Antithrombotics (2016) - CSL Behring : Haemostasis (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute Coronary Syndromes (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Medicines Company : Antithrombotics (2016) - Astra Zeneca : RWE research (2016)
Verheugt Freek	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : thrombosis (2016) - Daiichi Sankyo : thrombosis (2016) - Bayer Healthcare : thrombosis (2016) - Astrazeneca : thrombosis (2016) - Bristol Myers Squibb/Pfizer : thrombosis (2016)
Vranckx Pascal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : NOAC (2016) - Bayer Healthcare : NOAC (2016)
Zavatta Marco	Nothing to be declared (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Hyperlipidemia (2016) - Novartis : Hypertension (2016) - Boehringer-Ingelheim : Oral anticoagulation (2016) - Bayer Healthcare : Oral anticoagulation (2016) - Pfizer/BMS alliance : Oral anticoagulation (2016)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet treatment (2016)
Barbato Emanuele	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Education courses on rotational atherectomy (2016) - St Jude Medical : Educational courses on FFR (2016) D - Research funding (departmental or institutional). - St Jude Medical : Unrestricted grant for an investigator-driven study (2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Apixaban (2016) - Bristol Myers Squibb : Apixaban (2016) - Bayer : Aspirin, rivaroxaban (2016) - Abbott : BVS (2016) - MEDSCAPE-the heart.org : Inespecific (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016) - Astra Zeneca : Ticagrelor (2016) - Ferrer Internacional : Trinomia (polypill) (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Bueno Hector	E - Research funding (personal). <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2016) - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
Coca Antonio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Merck Serono : Bisoprolol-Amlodipine (2016) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016) - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016)
Collet Jean-Philippe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016) - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016)
Coman Ioan Mircea	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016) - Johnson & Johnson : antithrombotic (2016) - Bayer AG : antithrombotic (2016) - Sanofi Aventis : dyslipidemia (2016) - Fournier Laboratories : dyslipidemia (2016) - Amgen Inc : dyslipidemia , (2016) - Novartis : HF (2016) - Vifor International : iron deficiency (2016) - Actelion : PHT (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016) - Johnson & Johnson : antithrombotic (2016) - Bayer AG : antithrombotic (2016) - Sanofi Aventis : dyslipidemia (2016) - Amgen Inc : dyslipidemia (2016) - Fournier Laboratories : dyslipidemia (2016) - Novartis : HF (2016) - Vifor International : iron deficiency (2016) - Actelion : PHT (2016)
Delgado Victoria	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016)
Fitzsimons Donna	Nothing to be declared (2016)
Gaemperli Oliver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016)
Hindricks Gerhard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Biotronik : CIEDs and interventional electrophysiology (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016)
lung Bernard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016)
Juni Peter	Nothing to be declared (2016)
Katus Hugo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016) - Astra Zeneca : Ticagrelor (2016) - Bayer Vital : Xarelto-NOAK (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Katus Hugo	- Philips : MRT (2016)
Knuuti Juhani	D - Research funding (departmental or institutional). - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Medical : Echo course (2016) - Servier : Ischemic Heart Disease (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : NOAC (2016) - Medtronic : Structural disease (2016)
Leclercq Christophe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Biotronik : devices (2016) - Bayer Healthcare : DOAC (2016)
McDonagh Theresa	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Vifor International : Ferrinject (2016) - Novartis : Honoraria (2016)
Piepoli Massimo Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Committee member, Speaker fee (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<ul style="list-style-type: none"> - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulant, diabetes (2016) - Abbott Vascular : devices (2016) - Respicardia : devices (2016) - BioControl : devices (2016) - Novartis : heart failure (2016) - Cardiorentis : heart failure (2016) - Berlin Chemie AG : heart failure (2016) - Bayer Healthcare : heart failure (2016) - Vifor Pharma ltd : heart failure (2016) - CIBIEM : heart failure (2016) - Servier : heart failure, coronary artery disease (2016) - Amgen : heart failure, lipids (2016) - Pfizer : lipids (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Respicardia : anticoagulant (2016) - BioControl : devices (2016) - DC Device : devices (2016) - Novartis : heart failure (2016) - Cardiorentis : heart failure (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Bayer Healthcare : heart failure (2016) - CIBIEM : heart failure (2016) - Servier : heart failure, coronary artery disease (2016) - Amgen : heart failure, lipids (2016)
Richter Dimitrios	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : CAD- hypertension (2016) - Novartis : hypertension (2016) - Abbott : lipids (2016) - Amgen : lipids (2016) - Sanofi Aventis : Lipids (2016) - Lilly : Lipids (2016) - Unilever : lipids (2016) - Merck Sharp & Dohme : lipids (2016) - Angelini : Lipids (2016) - Vianex : lipids (2016) - Galenica : Lipids (2016) - Teva Pharmaceutical Industries : lipids, hypertension (2016) - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Bayer Healthcare : Thrombosis (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Terumo Inc : coronary catheters (2016) - Johnson & Johnson : coronary catheters (2016) - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Biotronik : devices (2016) - Terumo Inc : devices (2016) - Abbott Vascular : devices (2016)
Shlyakhto Evgeny	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2016) - Novartis : Arterial Hypertension, Heart Failure (2016) - Merck Sharp & Dohme : Atherosclerosis (2016) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016) - Pfizer : General Cardiology (2016)
Simpson Iain A	Nothing to be declared (2016)
Windecker Stephan	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : General Cardiology (2016) - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016) - Bracco Pharmaceutical : General Cardiology (2016)
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016)

Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none">- Pfizer : speaker CV risk factors. (2016)- MSD : speaker. CV risk factors (2016)D - Research funding (departmental or institutional).<ul style="list-style-type: none">- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)- Abbott : Epidemiology study of Mitral regurgitation (2016)